Using a series of in vitro assays and in vivo validation in PDX-PC models, we confirmed ARNTL2 is a reliable biomarker for predicting prognosis and therapeutic effects of erlotinib treatment in PC. This evidence concerns the gene BMAL2 and pachyonychia congenita.